May 11, 2022
FDA: Class I recall of certain Accula SARS-CoV-2 Tests
Editor's Note
The Food and Drug Administration (FDA) on May 9 identified the recall by Mesa Biotech, Inc, of certain Accula SARS-CoV-2 Tests as Class I, the most serious.
The recall was initiated because certain lots of the PCR test have an increased risk of giving false positive results because of contamination at the manufacturing facility.
Distribution dates were January 19 to February 8, 2022.
Free Daily News
- Surgical robotics market accelerates as new players challenge industry giants
- Robotic surgery boosts 3-year relapse-free survival in rectal cancer
- Low-cost simulation helps surgical trainees practice crisis skills for major hemorrhage
- Nurse leaders weigh in on NCLEX pass rate decline, impact on workforce readiness
- FDA issues early alerts on multiple high-risk device recalls from J&J, Medtronic, Baxter, Boston Scientific
- New UCSF measure shows 1 in 60 cesarean deliveries involve serious surgical complications
- Hospitals can curb costly post-acute discharges with targeted periop programs, study finds
- Sameness in nursing care puts patients at risk
- CMS’s plan to phase out inpatient-only list could bolster rural ASCs
- AAAHC unveils v44 standards to sharpen focus on patient-centered ambulatory care
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement